
    
      This study consists of two parts. In Part A, patients will receive MRG002 as a monotherapy at
      doses of 2.2 or 2.6 mg/kg intravenously (IV) over 60-90 minute on Day 1 of every 3 weeks
      (Q3W), to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). In
      part B, patients will receive a single IV infusion of MRG002 at RP2D on Day 1 of Q3W.
    
  